1. Inicio
  2. Publicaciones
  3. Exploring non-coding variants and evaluation of antisense oligonucleotides for splicing redirection in Usher syndrome

Exploring non-coding variants and evaluation of antisense oligonucleotides for splicing redirection in Usher syndrome

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Mínguez, P
  • Rodilla, C
  • Fernández-Caballero, L
  • Blanco-Kelly, F
  • Ayuso, C
  • Sanchis-Juan, A
  • Broekman, S
  • de Vrieze, E
  • van Wijk, E
  • Millán, JM

Grupos

Abstract

Exploring non-coding regions is increasingly gaining importance in the diagnosis of inherited retinal dystrophies. Deep-intronic variants causing aberrant splicing have been identified, prompting the development of antisense oligonucleotides (ASOs) to modulate splicing. We performed a screening of five previously described USH2A deep-intronic variants among USH2A monoallelic patients with Usher syndrome (USH) or isolated retinitis pigmentosa. Sequencing of entire USH2A or USH genes was then conducted in unresolved or newly monoallelic cases. The splicing impact of identified variants was assessed using minigene assays, and ASOs were designed to correct splicing. The screening allowed to diagnose 30.95% of the studied patients. The sequencing of USH genes revealed 16 new variants predicted to affect splicing, with four confirmed to affect splicing through minigene assays. Two of them were unreported deep-intronic variants and predicted to include a pseudoexon in the pre-mRNA, and the other two could alter a regulatory cis-element. ASOs designed for three USH2A deepintronic variants successfully redirected splicing in vitro. Our study demonstrates the improvement in genetic characterization of IRDs when analyzing non-coding regions, highlighting that deep-intronic variants significantly contribute to USH2A pathogenicity. Furthermore, successful splicing modulation through ASOs highlights their therapeutic potential for patients carrying deep-intronic variants.

Datos de la publicación

ISSN/ISSNe:
2162-2531, 2162-2531

Molecular Therapy Nucleic Acids  CELL PRESS

Tipo:
Article
Páginas:
-
PubMed:
39629117
Factor de Impacto:
1,852 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 4

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Proyectos y Estudios Clínicos

BETTER Better rEal-world healTh-daTa distributEd analytics Research platform

Investigador Principal: GEMA GARCÍA GARCÍA

101136262 . COMISION EUROPEA . 2023

Compartir